198 related articles for article (PubMed ID: 18192159)
1. Clinical approaches to minimize rash associated with EGFR inhibitors.
Oishi K
Oncol Nurs Forum; 2008 Jan; 35(1):103-11. PubMed ID: 18192159
[TBL] [Abstract][Full Text] [Related]
2. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum.
Pérez-Soler R; Delord JP; Halpern A; Kelly K; Krueger J; Sureda BM; von Pawel J; Temel J; Siena S; Soulières D; Saltz L; Leyden J
Oncologist; 2005 May; 10(5):345-56. PubMed ID: 15851793
[TBL] [Abstract][Full Text] [Related]
3. Management of the cutaneous side effects of therapeutic epidermal growth factor receptor inhibition.
Reck M; Gutzmer R
Onkologie; 2010; 33(8-9):470-9. PubMed ID: 20838065
[TBL] [Abstract][Full Text] [Related]
4. What kind of rash is it?: deciphering the dermatologic toxicities of biologic and targeted therapies.
Esper P; Gale D; Muehlbauer P
Clin J Oncol Nurs; 2007 Oct; 11(5):659-66. PubMed ID: 17962174
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.
Lynch TJ; Kim ES; Eaby B; Garey J; West DP; Lacouture ME
Oncologist; 2007 May; 12(5):610-21. PubMed ID: 17522250
[TBL] [Abstract][Full Text] [Related]
6. Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy.
Tejwani A; Wu S; Jia Y; Agulnik M; Millender L; Lacouture ME
Cancer; 2009 Mar; 115(6):1286-99. PubMed ID: 19170238
[TBL] [Abstract][Full Text] [Related]
7. EGFR-targeted therapy and related skin toxicity.
Morse L; Calarese P
Semin Oncol Nurs; 2006 Aug; 22(3):152-62. PubMed ID: 16893744
[TBL] [Abstract][Full Text] [Related]
8. Pimecrolimus cream 1% for the treatment of papulopustular eruption related to epidermal growth factor receptor inhibitors: a case series and a literature review of therapeutic approaches.
Nikolaou V; Stratigos A; Antoniou C; Kiagia M; Nikolaou C; Katsambas A; Syrigos K
Dermatology; 2010; 220(3):243-8. PubMed ID: 20110632
[TBL] [Abstract][Full Text] [Related]
9. Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among German oncologists.
Hassel JC; Kripp M; Al-Batran S; Hofheinz RD
Onkologie; 2010; 33(3):94-8. PubMed ID: 20215799
[TBL] [Abstract][Full Text] [Related]
10. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results.
Boone SL; Rademaker A; Liu D; Pfeiffer C; Mauro DJ; Lacouture ME
Oncology; 2007; 72(3-4):152-9. PubMed ID: 18160805
[TBL] [Abstract][Full Text] [Related]
11. Manage skin toxicities associated with EGFR inhibitors.
Becze E
ONS Connect; 2008 Jun; 23(6):22-3. PubMed ID: 18572873
[No Abstract] [Full Text] [Related]
12. Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors.
Tan EH; Chan A
Ann Pharmacother; 2009 Oct; 43(10):1658-66. PubMed ID: 19755624
[TBL] [Abstract][Full Text] [Related]
13. Preemptive management of dermatologic toxicities associated with epidermal growth factor receptor inhibitors.
Boucher J; Olson L; Piperdi B
Clin J Oncol Nurs; 2011 Oct; 15(5):501-8. PubMed ID: 21951736
[TBL] [Abstract][Full Text] [Related]
14. Toward evidence-based management of the dermatologic effects of EGFR inhibitors.
LoRusso P
Oncology (Williston Park); 2009 Feb; 23(2):186-94. PubMed ID: 19323301
[TBL] [Abstract][Full Text] [Related]
15. Anticipating and managing the cutaneous side effects of epidermal growth factor receptor inhibitors.
Sinclair R
Asia Pac J Clin Oncol; 2014 Mar; 10 Suppl 1():11-7. PubMed ID: 24512509
[TBL] [Abstract][Full Text] [Related]
16. Side effects of targeted therapies: rash.
Eaby-Sandy B; Lynch K
Semin Oncol Nurs; 2014 Aug; 30(3):147-54. PubMed ID: 25085026
[TBL] [Abstract][Full Text] [Related]
17. Common side effects of anti-EGFR therapy: acneform rash.
Sipples R
Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):28-34. PubMed ID: 16616284
[TBL] [Abstract][Full Text] [Related]
18. Clinical research of EGFR inhibitors and related dermatologic toxicities.
Perez-Soler R; Van Cutsem E
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):10-6. PubMed ID: 18154213
[TBL] [Abstract][Full Text] [Related]
19. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy.
Eilers RE; Gandhi M; Patel JD; Mulcahy MF; Agulnik M; Hensing T; Lacouture ME
J Natl Cancer Inst; 2010 Jan; 102(1):47-53. PubMed ID: 20007525
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapies in colorectal carcinoma: addressing toxicities associated with EGFR inhibitors.
Biedrzycki BA
ONS Connect; 2007; 22(8 Suppl):33-4. PubMed ID: 17824555
[No Abstract] [Full Text] [Related]
[Next] [New Search]
